We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
MGB Biopharma Succeeds in Developing an IV Formulation of MGB-BP-3
News

MGB Biopharma Succeeds in Developing an IV Formulation of MGB-BP-3

MGB Biopharma Succeeds in Developing an IV Formulation of MGB-BP-3
News

MGB Biopharma Succeeds in Developing an IV Formulation of MGB-BP-3

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "MGB Biopharma Succeeds in Developing an IV Formulation of MGB-BP-3"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

MGB Biopharma has announced that it has developed a stable intravenous (IV) formulation of MGB-BP-3, designed for the treatment of systemic susceptible and resistant Gram-positive hospital-acquired infections.

The intravenous formulation of MGB-BP-3 is currently in late stage pre-clinical development, where it is being assessed in a number of models for tolerability and efficacy against specific Gram-positive bacteria, which can cause many of the most common hospital-acquired infections. The foci of these proof of concept studies have been methicillin-resistant Staphylococcus aureus (MRSA), and Streptococcus pneumoniae. MGB-BP-3 has been successfully lyophilized, forming a freeze-dried formulation that is suitable for IV administration in aqueous solution.

MGB-BP-3 is a truly novel antibiotic which has been shown to be active against a broad range of important multi-resistant Gram-positive pathogens. The Company has made significant progress in developing an oral formulation of MGB-BP-3 for the treatment of Clostridium difficile that is due to begin a Phase I clinical study in the coming weeks.

Today’s announcement comes at a critical time for the antibiotic industry, in light of the latest report from the O’Neill Review on Antibiotic Resistance (14th May 2015), which highlighted the human and financial costs that society faces as a result of antibiotic resistant infections, one of the world’s most pressing global healthcare problems.

Miroslav Ravic, CEO of MGB Biopharma, said: “The development of this new IV formulation is a fantastic breakthrough for MGB. I would like to congratulate all of the team who were responsible for making this possible. With this new formulation we can increase the utility of MGB-BP-3 significantly as it could allow us to provide clinicians with a truly novel antibiotic to treat the multiple resistant systemic Gram-positive infections that cause many deaths and higher morbidity in patients being treated in hospital.”

“The figures highlighted in Jim O’Neill’s report - and in particular the potential human cost of not addressing antibiotic resistance - are significant. There is a clear need for novel and differentiated products to tackle the growing concern of antimicrobial resistance (AMR). MGB Biopharma is one of the very few companies in the world developing a completely novel class of antibiotic capable of combating AMR.”

Advertisement